Patent Grant
11389370
This invention relates to the field of treating the blood sugar levels of diabetic patients with acoustic pressure pulse shock waves generally. More specifically to treating the abnormally high conditions found in a diabetic using shock waves that are generated as either focused waves at high or low energy levels or non-focused waves at preferably low energy levels or a combination of such waves. Additionally, using an optimized shock wave treatment protocol for age related skeletal muscle tissue regenerating and optimized athletic performances and muscle resilience without steroids.
On Dec. 20, 2006 the United Nations General Assembly passed a landmark resolution recognizing diabetes as a global pandemic. This is a first for a non-infectious disease. This resolution led by the International Diabetes Federation has brought global attention to a disease that affects 246 million people living with diabetes. On Nov. 14, 2007 the UN will observe the First World Diabetes Day.
The financial burden of diabetes is tremendous. The direct and indirect costs associated with both forms of diabetes, type 1 and type 2, in the United States during 2002 were estimated to be $132 billion. The average annual health care costs for a person with diabetes are $13,243, which is 2.4 times greater than those for an individual without diabetes. In 2002, 11 percent of national health care expenditures were directed to diabetes care. The costs of treating the complications of diabetes, which both forms of the disease share in common, account for much of the health care costs associated with the disease. Although estimates of the rates of diabetes have increased since 2002, the associated cost estimates have not yet been revised; hence, the economic data given here are conservative. Clearly, the economic and societal burden of diabetes has a profound impact on the Nation.
Type 1 diabetes is an autoimmune disease in which the body's own immune system attacks and destroys specialized cells of the vascular system called beta cells. Beta cells are found within tiny clusters called islets and produce the hormone insulin. Insulin is required for survival; it sends signals to the body's cells and extremities, telling them to absorb glucose to use as a fuel. Without this vital hormone, the cells and extremities do not absorb glucose and patients can starve to death, despite having high levels of glucose in their bloodstream. An interplay of genetic and environmental factors is responsible for the onset of type 1 diabetes (as well as type 2 diabetes). Having a family member with the disease puts one at higher risk for developing type 1 diabetes.
Type 1 diabetes differs from type 2 diabetes—type 2 is more commonly diagnosed in adulthood, is strongly associated with overweight and obesity and disproportionately affects minority populations. Although patients with type 1 diabetes require externally administered insulin to survive, type 2 diabetes patients may be treated with medications that make their extremities more sensitive to insulin or enhance insulin production or, in some cases, may be treated with insulin itself.
The treatment of patients with type 1 diabetes was revolutionized in 1921 with the discovery of insulin by a group of researchers at the University of Toronto. To this day, insulin therapy continues to save the lives of patients with type 1 diabetes by replacing the essential hormone what their bodies no longer adequately produce. However, insulin therapy, whether through injections or via a pump, is not a cure and it cannot prevent complications. To manage the disease, patients must carefully monitor their food intake and physical activity. They must perform painful finger sticks multiple times a day to draw blood and test their glucose levels. Based on this monitoring, patients often give themselves several shots of insulin a day, or calculate the correct amount of insulin to administer through their insulin pumps. This regimen is not just “once in a while;” it is every day of their lives. As many patients and their parents say; “There is never a day off from diabetes”. Moreover, no matter how vigilant patients are at regulating their blood glucose levels, they can never achieve the fine tuned regulation provided by a healthy vascular system, which exquisitely senses and responds to insulin needs with precise timing.
In 1980 the development of the first animal model of type 1 diabetes that could be used to test drugs for type 1 diabetes; non-obese diabetic (NOD) mouse. Using these NOD mice, doctors from Toronto, the birthplace of insulin discovery, made a revolutionary discovery.
On Dec. 15, 2006, in Canada, a publication in Canada.com reported a Toronto scientist actually appeared to have cured diabetic mice by manipulating the nerves surrounding the insulin-producing islets. Dr. Dosch as early as 1999 concluded that there were surprising similarities between diabetes and multiple sclerosis a central nervous system disease. He suspected a link between the nerves and diabetes. In the article, Dr. Dosch and Dr. Salter used capsaicin, the active ingredient in hot peppers, to kill the pancreatic sensory nerves in mice that had the equivalent of Type 1 diabetes. Once the nerves were deactivated, the islets began producing insulin normally. They had discovered the nerves secrete neuropeptides that are instrumental in the proper functioning of the islets. The University of Calgary and the Jackson Laboratory in Maine found the nerves in diabetic mice were releasing too little of the neuropeptides, resulting in a “vicious cycle” of stress on the islets. In a trial they injected neuropeptide “substance P” in the vascular system of diabetic mice. The islet inflammation cleared up and the diabetes was gone with just one injection. In this study they also discovered that their treatments curbed the insulin resistance that is the hallmark of Type 2 diabetes, and that the insulin resistance is a major factor in Type 1 diabetes, suggesting the two illnesses are quite similar. This research has yet to be tested in clinical trials on humans, but if confirmed it may lead to an eradication of both Type 1 and 2 diabetes.
Solutions to the problem of diabetic disease often involve the use of medications. the most promising appear to be those that can enhance the natural body system called the incretin system, which helps regulate glucose by affecting the beta cells and alpha cells in the vascular system. These prescription medications called dipeptidyl peptidase-4(DPP-4) inhibitors improve blood sugar control in patients with type 2 diabetes. Through DPP-4 inhibition this new class of drug works when the blood sugar is elevated due to beta-cell dysfunction and uncontrolled production of glucose by the liver due to alpha cell and beta cell dysfunction.
Preferably, these new classes of medications and treatments for diabetes can be more effective when initiated or alternatively combined with the novel use of acoustic shock wave treatments. It is therefore an object of the present invention to treat the vascular system or liver of diabetic diagnosed patients or at risk patients with an extremity regenerating shock wave treatment.
It is also an object of the present invention to provide a shock wave therapy that employs a more effective wave energy transmission, that is both simple to deploy and less target sensitive when compared to reflected focused waves.
It is a further object of the invention to provide a therapeutic treatment of a large target area for subsurface soft extremities of organs such as the vascular system or liver to treat diseases including, but not limited to diabetes.
C. J. Wang discovered that a variety of substances displaying high biological activity are released during and after the application of shock waves to extremity. The production of nitric oxygen (NO), vessel endothelial growth factor (VEGF), bone morphogenetic protein (BMP), and other growth factors have been demonstrated. Furthermore, Maier discovered a decline in the number of small-myelinized neurons after shock wave therapy, an observation that could explain the analgesic effect of shock wave therapy. As a consequence of these findings, the mechanistic model was increasingly relegated to a secondary role and supplanted by a microbiological model explaining the action of shock waves.
In practice the use of ESWT has been a results oriented science wherein a clear and accurate understanding of the actual healing process was neither understood nor fully appreciated. As a result a variety of treatments and uses of ESWT in mammals had heretofore never been tried or attempted or if tried, the outcomes were at best mixed.
A primary factor in the reluctance to use ESWT was that the believed threshold energy requirements were so high that the surrounding extremity would hemorrhage, exhibited by hematomas and bleeding around the treated site. This phenomenon is particularly known in the area of focused emitted waves designed for deep penetration into the patient. US patent publication 2005/0010140 recites the disadvantageous effects of cavitation phenomena can be controlled wherein the shock wave source is connected to a control means which controls the release frequency of shock waves as a function of pulse energy in such a manner that higher pulse energy correlates with lower release frequencies of the shock waves and vice versa. The avoidance of cavitation occurrences would it is postulated result in far less pain for the patient.
In US 2006/0246044 published on Nov. 2, 2006, Andreas Lutz of Dornier Med Tech Systems in Germany disclosed “Methods for Improving Cell Therapy and Extremity Regeneration in Patients With Cardiovascular Disease by Means of Shockwaves”. In this application the use of shock waves is used in combination with cell therapy to assist in heart or neurological extremity regeneration.
The present invention recognizes the underlying beneficial attributes of ESWT are not now and may never be fully comprehended, however, under a more advanced molecular theory the authors of the present invention postulated a microbiological model suggesting the response mechanism to such treatment.
This model attempts to explain the effect of ESWT by postulating neovascularization of the treated extremity with simultaneous release of diverse growth factors. The enhanced metabolic activity taking place in the presence of these growth factors could be responsible for the healing of the chronically inflamed extremity while the decrease in afferent nerve fibers causes the analgesic effect.
The present inventors see that ESWT is a highly versatile therapeutic instrument. It can be used as a bioengineering tool to achieve effects such as the production of growth factors or as a surgical instrument to effect an extremely subtle type of denervation. In the field of traumatology, these properties are used primarily to treat fractures with non-union or delayed osseous union. ESWT is also becoming increasingly important for treating the early stages of osteochondritis dissecans. Heretofore the use of ESWT has never been used as a therapeutic instrument in the treatment of diabetes until the attempt to directly treat a pancreas of a diabetic to control insulin production to prevent over production caused by the pancreas as was described in U.S. Pat. No. 7,988,648 granted Aug. 2, 2011. In this prior art patent, the inventors taught treatment methods for stimulating the tissue of a subsurface organ that was part of the incretin system. New data unexpectedly has been discovered suggesting a new preventative treatment for diabetic that is a remote method of controlling blood sugar levels. As used herein, remote means emitting the pressure pulses or acoustic shock waves through the limb extremity along a path through the skin and into muscle tissue.
These and other applications of the present invention are described more fully as follows with first detailed description of shock wave therapeutic methods and then a detailed description of several shock wave devices and apparati for carrying out the methods.
The method of treating red blood cells of a human patient has the steps of: activating an acoustic shock wave generator or source to emit acoustic shock waves; and subjecting a vascular system containing red blood cells and surrounding muscle tissue peripherally through a limb extremity of a patient to the acoustic shock waves by stimulating the limb extremity wherein the limb extremity is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves.
The emitted shock waves are divergent or near planar or can be convergent having a geometric focal volume or point at a distance of at least X from the generator or source. The patient can be diabetic exhibiting type 1 or type 2 diabetes condition. The limb extremity can be a leg, a foot, a hand or an arm. The patient has an elevated baseline blood sugar level prior to treating which lowers after treatment. Ideally, repeating the method periodically a plurality of times over a period of weeks to lower said baseline level of blood sugar to normal levels. The method can be a preventive shock wave therapy having the steps of: identifying a diabetic at risk patient, the patient having an at risk baseline blood sugar level; and subjecting the at risk extremity to shock waves to lower said baseline sugar level. The step of identifying an at risk patient includes one or more indications of risk based on family history, genetic disposition, physical condition, or blood or extremity analysis. The step of testing the at risk patient to establish measured the baseline condition pre shock wave therapy is used as well as post shockwave therapy testing the blood sugar level for comparison to the baseline condition. Repeating the method periodically a plurality of times over a period of weeks lowers said baseline level of blood sugar.
In another embodiment, a method of treating skeletal muscle tissue of an aging human patient has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves and subjecting surrounding muscle tissue peripherally to the acoustic shock waves by stimulating the muscle tissue wherein the muscle tissue is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves.
Preferably, the emitted shock waves are of a low intensity ranging from 0.10-0.12 mJ/mm2. In still another method of treating skeletal muscle tissue of a human patient to optimize athletic performance and muscle resilience comprises the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves and subjecting surrounding muscle tissue peripherally to the acoustic shock waves by stimulating the muscle tissue wherein the muscle tissue is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves. Preferably, the emitted shock waves are of a low intensity ranging from 0.10-0.14 mJ/mm2. The emitted shock waves cause a quick removal of lactic acid from the cells of the muscle tissue allowing quicker muscle recovery. The treatment can even be used for erectile dysfunction or penis performance enhancement.
A “pressure pulse” according to the present invention is an acoustic pulse which includes several cycles of positive and negative pressure. The amplitude of the positive part of such a cycle should be above about 0.1 MPa and its time duration is from below a microsecond to about a second. Rise times of the positive part of the first pressure cycle may be in the range of nano-seconds (ns) up to some milli-seconds (ms). Very fast pressure pulses are called shock waves. Shock waves used in medical applications do have amplitudes above 0.1 MPa and rise times of the amplitude are below 100 ns. The duration of a shock wave is typically below 1-3 micro-seconds (μs) for the positive part of a cycle and typically above some micro-seconds for the negative part of a cycle.
A “paraboloid” according to the present invention is a three-dimensional reflecting bowl. In two dimensions (in Cartesian coordinates, x and y) the formula y2=2px, wherein p/2 is the distance of the focal point of the paraboloid from its apex, defines the paraboloid. Rotation of the two-dimensional figure defined by this formula around its longitudinal axis generates a de facto paraboloid.
A “generalized paraboloid” according to the present invention is also a three-dimensional bowl. In two dimensions (in Cartesian coordinates, x and y) the formula yn=2px [with n being ≠2, but being greater than about 1.2 and smaller than 2, or greater than 2 but smaller than about 2.8]. In a generalized paraboloid, the characteristics of the wave fronts created by electrodes located within the generalized paraboloid may be corrected by the selection of (p (−z,+z)), with z being a measure for the burn down of an electrode, and n, so that phenomena including, but not limited to, burn down of the tip of an electrode (−z,+z) and/or disturbances caused by diffraction at the aperture of the paraboloid are compensated for.
Waves/wave fronts described as being “focused” or “having focusing characteristics” means in the context of the present invention that the respective waves or wave fronts are traveling and increase their amplitude in direction of the focal point. Per definition the energy of the wave will be at a maximum in the focal point or, if there is a focal shift in this point, the energy is at a maximum near the geometrical focal point. Both the maximum energy and the maximal pressure amplitude may be used to define the focal point.
“Divergent waves” in the context of the present invention are all waves which are not focused and are not plane or nearly plane. Divergent waves also include waves which only seem to have a focus or source from which the waves are transmitted. The wave fronts of divergent waves have divergent characteristics. Divergent waves can be created in many different way, for example: A focused wave will become divergent once it has passed through the focal point. Spherical waves are also included in this definition of divergent waves and have wave fronts with divergent characteristics.
“Plane waves” are sometimes also called flat or even waves. Their wave fronts have plane characteristics (also called even or parallel characteristics). The amplitude in a wave front is constant and the “curvature” is flat (that is why these waves are sometimes called flat waves). Plane waves do not have a focus to which their fronts move (focused) or from which the fronts are emitted (divergent). “Nearly plane waves” also do not have a focus to which their fronts move (focused) or from which the fronts are emitted (divergent). The amplitude of their wave fronts (having “nearly plane” characteristics) is approximating the constancy of plain waves. “Nearly plane” waves can be emitted by generators having pressure pulse/shock wave generating elements with flat emitters or curved emitters. Curved emitters may comprise a generalized paraboloid that allows waves having nearly plane characteristics to be emitted.
A “curved emitter” is an emitter having a curved reflecting (or focusing) or emitting surface and includes, but is not limited to, emitters having ellipsoidal, parabolic, quasi parabolic (general paraboloid) or spherical reflector/reflecting or emitting elements. Curved emitters having a curved reflecting or focusing element generally produce waves having focused wave fronts, while curved emitters having a curved emitting surfaces generally produce wave having divergent wave fronts.
“AIDS” An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
“Crohn's disease” (also known as regional enteritis) is a chronic, episodic, inflammatory condition of the gastrointestinal tract characterized by transmural inflammation (affecting the entire wall of the involved bowel) and skip lesions (areas of inflammation with areas of normal lining in between). Crohn's disease is a type of inflammatory bowel disease (IBD) and can affect any part of the gastrointestinal tract from mouth to anus; as a result, the symptoms of Crohn's disease can vary between affected individuals. The main gastrointestinal symptoms are abdominal pain, diarrhea, which may be bloody, and weight loss. Crohn's disease can also cause complications outside of the gastrointestinal tract such as skin rashes, arthritis, and inflammation of the eye.
“diabetes” A heterogeneous group of disorders that share glucose intolerance in common.
“HIV” Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.
The invention will be described by way of example and with reference to the accompanying drawings in which:
With reference to
With reference to
With reference to
A case series by Kenneth Craig Vincent, Medical Director—Kompass Health Associates, Auckland, New Zealand, attempting to improve skeletal muscle function in the older adult population derived some interesting complimentary data. The application of shockwave treatment (SWT) utilizing a DermaGold-100 (TRT LLC, USA) not only improved muscle mass, balance, and stability across the 10 trial subjects, but simultaneously indicated that blood sugar levels of three (3) of the diabetic subjects noticed an improvement in both fasting (Table 1) and postprandial (Table 2) blood sugar levels after 3 sessions of SWT.
The treatment protocol involved the application of SWT onto the hamstrings, gastrocnemius/soleus complex, and the planter aspect of the foot. Three session of SWT were applied onto to each subject over a one week interval.
These figures suggest that the increase in skeletal muscle mass and activity would increase metabolic demand and simultaneously increase blood sugar uptake, improving both fasting and postprandial blood sugar levels in diabetic patients. It is therefore plausible to hypothesize that application of an increased number of SWT impulses over the skeletal muscle of the lower extremity could help improve the control of blood sugar levels in diabetics.
Accordingly, a periodic treatment regimen of emitting 500 or more shock wave pressure pulses, preferably about 1500 pressure pulses at a low pulse energy of 0.1 mJ/mm2 or higher up to 1.0 mJ/mm2, preferably about 0.3 to 0.5 mJ/mm2 over a period of weeks on the limb extremity 100, 100A, 100F, 100T will remotely improve the patient's high baseline blood sugar levels to approach, if not achieve, normal blood sugar levels.
The following description of the proper amplitude and pressure pulse intensities of the shock waves 200 are provided below along with a description of how the shock waves actually function and have been taken from the co-pending application of the present inventors and replicated herein as described below. For the purpose of describing the shock waves 200 were used as exemplary and are intended to include all of the wave patterns discussed in
This method of treatment has the steps of, locating a treatment site, generating either convergent diffused or far-sighted focused shock waves or unfocused shock waves, of directing these shock waves to the treatment site; and applying a sufficient number of these shock waves to induce activation of one or more growth factor thereby inducing or accelerating healing.
The unfocused shock waves can be of a divergent wave pattern or near planar pattern preferably of a low peak pressure amplitude and density. Typically the energy density values range as low as 0.000001 mJ/mm2 and having a high end energy density of below 1.0 mJ/mm2, preferably 0.20 mJ/mm2 or less. The peak pressure amplitude of the positive part of the cycle should be above 1.0 and its duration is below 1-3 microseconds.
The treatment depth can vary from the surface to the full depth of the human or animal torso and the treatment site can be defined by a much larger treatment area than the 0.10-3.0 cm2 commonly produced by focused waves. The above methodology is particularly well suited for surface as well as sub-surface soft tissue treatments.
While one of the benefits of the non-invasive nature of this treatment relates to reducing patient recovery and healing time, the fact that the treatments can be delivered at dosages well below the threshold of pain means that no local or general anesthesia is typically required as a consequence of the treatment. This alone significantly reduces any risk factors or complications associated with pain management during the procedure. The treatments further can reduce the need for a regiment of chemical or drug therapies before or after exposure to this shock wave therapy. Alternatively, ESWT can be used in conjunction with chemical or drug therapies to increase the cellular response permitting an opportunity to lower dosages of such chemicals or drugs while increasing the therapeutic efficiency. This is a particularly useful tool for the physician whose patient is elderly, a smoker or with an immune system deficiency which would complicate if not make unavailable more traditional invasive surgical procedures. In fact the above methodology proposed in this patent may be the first if not only choice of treatment available for patients in this class wherein heretofore conventional procedures were deemed too risky.
A further clinical benefit of the above methodology is that the procedure can be done either as an outpatient treatment or at a doctor's office assuming the patient's condition does not otherwise require hospitalization.
The stimulation of growth factors and activation of healing acceleration is particularly valuable to elderly patients and other high risk factor subjects.
Even more striking as mentioned earlier, early prevention therapies can be employed to stimulate extremity or organ modeling to be maintained within acceptable ranges prior to a degeneration occurring. This is extremely valuable in the prevention of diabetes or heart disease for example. The methods would be to identify at risk patients based on family history or genetic disposition, physical condition, etc. and subjecting that patient to therapeutic shock wave therapy for the purpose of stimulating extremity repair effectively remodeling the patient's susceptible organ to be within accepted functional parameters. The objective being to preventively stimulate cellular repairs to preemptively avoid a degenerative condition from occurring which may require invasive surgical procedures.
This apparatus may, in certain embodiments, be adjusted/modified/or the complete shock wave head or part of it may be exchanged so that the desired and/or optimal acoustic profile such as one having wave fronts with focused, nearly plane or divergent characteristics can be chosen.
A change of the wave front characteristics may, for example, be achieved by changing the distance of the exit acoustic window relative to the reflector, by changing the reflector geometry, by introducing certain lenses or by removing elements such as lenses that modify the waves produced by a pressure pulse/shock wave generating element. Exemplary pressure pulse/shock wave sources that can, for example, be exchanged for each other to allow an apparatus to generate waves having different wave front characteristics are described in detail below.
In certain embodiments, the change of the distance of the exit acoustic window can be accomplished by a sliding movement. However, in other embodiments of the present invention, in particular, if mechanical complex arrangements, the movement can be an exchange of mechanical elements.
In one embodiment, mechanical elements that are exchanged to achieve a change in wave front characteristics include the primary pressure pulse generating element, the focusing element, the reflecting element, the housing and the membrane. In another embodiment, the mechanical elements further include a closed fluid volume within the housing in which the pressure pulse is formed and transmitted through the exit window.
In one embodiment, the apparatus of the present invention is used in combination therapy. Here, the characteristics of waves emitted by the apparatus are switched from, for example, focused to divergent or from divergent with lower energy density to divergent with higher energy density. Thus, effects of a pressure pulse treatment can be optimized by using waves having different characteristics and/or energy densities, respectively.
While the above described universal toolbox of the present invention provides versatility, the person skilled in the art will appreciate that apparatuses that only produce waves having, for example, nearly plane characteristics, are less mechanically demanding and fulfill the requirements of many users.
As the person skilled in the art will also appreciate that embodiments shown in drawings 4A-4C and 5A-5C are independent of the generation principle and thus are valid for not only electro-hydraulic shock wave generation but also for, but not limited to, PP/SW generation based on electromagnetic, piezoceramic and ballistic principles. The pressure pulse generators may, in certain embodiments, be equipped with a water cushion that houses water which defines the path of pressure pulse waves that is, through which those waves are transmitted. In a preferred embodiment, a patient is coupled via ultrasound gel or oil to the acoustic exit window (17), which can, for example, be an acoustic transparent membrane, a water cushion, a plastic plate or a metal plate.
With reference to
With particular reference to
With reference to
With reference to
As shown the use of these acoustic wave forms can be used separately or in combination to achieve the desired therapeutic effect.
Furthermore such acoustic wave forms can be used in combination with drugs, chemical treatments, irradiation therapy or even physical therapy and when so combined the stimulated cells will more rapidly assist the body's natural healing response.
The present invention provides an apparatus for an effective treatment of indications, which benefit from low energy pressure pulse/shock waves having nearly plane or even divergent characteristics. For the treatment of those indications, the procedure to locate the area to which the pressure pulses/shock waves are applied often needs to be less accurate than, e.g., when kidney stones are destroyed with focused waves. In fact, sometimes the knowledge of the physique of the subject to be treated is sufficient, so that imaging devices like ultrasound, x-ray or similar, as they are known from devices used in the destruction of kidney stones, may not be required. The area of the focal point/focus volume can be enlarged by reducing the focusing or even by eliminating it all together by using an apparatus according to the present invention which produces waves having wave fronts with nearly plane or divergent characteristics.
With an unfocused wave having nearly plane wave characteristic or even divergent wave characteristics, the energy density of the wave may be or may be adjusted to be so low that side effects including pain are very minor or even do not exist at all.
In certain embodiments, the apparatus of the present invention is able to produce waves having energy density values that are below 0.1 mJ/mm2 or even as low as 0.000001 mJ/mm2. In a preferred embodiment, those low end values range between 0.1-0.001 mJ/mm2. With these low energy densities, side effects are reduced and the dose application is much more uniform. Additionally, the possibility of harming surface extremity is reduced when using an apparatus of the present invention that generates waves having nearly plane or divergent characteristics and larger transmission areas compared to apparatuses using a focused shock wave source that need to be moved around to cover the affected area. The apparatus of the present invention also may allow the user to make more precise energy density adjustments than an apparatus generating only focused shock waves, which is generally limited in terms of lowering the energy output.
The treatment of the above mentioned diabetic indications are believed to be a first time use of acoustic shock wave therapy. None of the work done to date has treated the above mentioned indications with convergent, divergent, planar or near-planar acoustic shock waves of low energy.
In another treatment therapy, extracorporeal shockwave treatments are used to improve motion integrity and independence in the aging population via the regenerative enhancement of skeletal muscle tissue. The maintenance of balance is an essential task necessary for both static and dynamic stability and motion independence. Age related skeletal muscle atrophy and sarcopenia resulting in the loss of muscle capacity and mass in the elderly negatively impacts physical capacity, daily function, quality of life, and constitutes a growing global healthcare burden. Progressive motor neuron degeneration, increases in fat mass, decreases in lean muscle, bone mass, and cellular environmental aberrances are commonly seen alterations of aging muscle. This leads to impairments in metabolic rate, aerobic capacity, strength and balance, functional capacity, along with emotional and cognitive distress all of which can be improved and the degradation reversed by the use of low energy unfocused acoustic shock waves.
Method of intervention uses low-intensity extracorporeal shockwave treatment (ESWT) ranging from 0.10-0.12 mJ/mm2 to introduce a positive biocellular response in aging skeletal muscles. This ESWT can be utilized to reverse the effects of age related skeletal muscle atrophy and sarcopenia due to regenerative enhancement stimulated by shockwaves. These regenerative enhancements target a variety of myogenic transforming and regenerative growth factors via several mechanisms such as: integrin signaling, transforming growth factor beta-1 proliferation, immune-modulations, overt and covert inflammatory regulation, and progenitor cell expression among others. Unlike most interventions that commonly target or influence a narrow spectrum of a given pathology or condition, ESWT has a much boarder spectrum of influence on human tissue, as in the instance of skeletal muscle tissue. In an initial pilot series of Ten (10) older adult subjects, the inventors found that three (3) sessions of ESWT focused on several lower extremity muscle groups helped enhance muscle regeneration, improve postural and dynamic balance, and reduce activity related fatigue, improving quality of life and emotional resilience in our subjects. This occurred interestingly at a narrow optimized energy range. While the early work on tissue shows improvement, this targeted range optimizes the response.
In a third refinement, extracorporeal shockwave treatments are used to optimize athletic performance and muscle resilience. The pathogenesis of musculoskeletal overuse syndromes have come under much discussion and is commonly accepted to be the consequence of disrepair leading to degenerative syndromes with a constellation of contributory and aberrant propagating co-factors. Despite advances in sports medicine the ability to optimize athletic performance safely while preventing injuries remains elusive and an enigma.
The treatment method of intervention Low-intensity uses extracorporeal shockwave treatment (ESWT) ranging from 0.10-0.14 mJ/mm2 to introduce a positive biocellular response in healthy actively competitive athletes to help improve muscle resilience in order to perform a given task with lest exertion due to optimized muscle output levels. These regenerative enhancements target a variety of myogenic transforming and regenerative growth factors via a unique stimulus related biomechano-transduction pathway that positively influences: integrin signaling, transforming growth factor beta-1 proliferation, immune-modulations, overt and covert inflammatory regulation, and progenitor cell expression among others. Unlike most interventions that commonly target or influence a narrow spectrum of a given pathology or condition,
ESWT has a much boarder spectrum of influence on human tissue, as in the instance of skeletal muscle tissue. In an initial pilot series of eight (8) athletic subjects, the inventors found that three (3) sessions of ESWT focused on several muscle groups helped enhance the energy output of skeletal muscles providing for economics in effort to complete and perform a given task. This further suggests that the ability to prevent overuse and fatigue related syndromes among athletes is made possible by the increased resilience and energy capacity economics influenced by ESWT in skeletal muscle tissue.
In particular with athletes, this optimized shock wave treatment can be useful to quickly remove lactic acid from cells after a workout. This leads to quicker muscle recovery. This quick recovery in combination with hydration can rapidly diminish muscle cramping in athletes. This is a legal performance enhancing therapy that can achieve the results of “banned” steroid for athletes without introducing any pharmacologically prohibited drugs or stimulants. The therapy achieves everything that steroids do, but legally.
Certain enzymes prevent the propagation and or satellite stem cells found in striated muscles. ESWT reverse the effects of those enzymes allowing for the immediate replication of striated muscle cells. Enzymes act as a “governor” of sorts limiting cell replication, ESWT removes or reduces the governor or limiting effect. Return to normal cell growth is slow versus ESWT which has an optimized cell response by achieving a rapid optimal reset of the clock. When treating healthy males for erectile dysfunction, improves vitality, increases length and girth of penis, similar to the effects of steroids on muscles. This allows not only a return to normal, better than normal. It is quite normal for adult with bad eating and exercise habits to have increased blood sugar/diabetes, as discussed, these treatments can reverse blood sugar levels to normal, reverse aging and enhance muscle tissue growth in the extremities as well as the penis.
It will be appreciated that the apparatuses and processes of the present invention can have a variety of embodiments, only a few of which are disclosed herein. It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3951140 | Eggleton et al. | Apr 1976 | A |
| 4539989 | Forssmann et al. | Sep 1985 | A |
| 4807627 | Eisenmenger | Feb 1989 | A |
| 4868161 | Roberts | Sep 1989 | A |
| 4905671 | Senge et al. | Mar 1990 | A |
| 5119801 | Eizenhoefer et al. | Jun 1992 | A |
| 5173295 | Wehling | Dec 1992 | A |
| 5174280 | Gruenwald et al. | Dec 1992 | A |
| 5222484 | Krauss et al. | Jun 1993 | A |
| 5314457 | Jeutter et al. | May 1994 | A |
| 5419335 | Hartmann | May 1995 | A |
| 5545124 | Krause et al. | Aug 1996 | A |
| 5595178 | Voss et al. | Jan 1997 | A |
| 6036661 | Schwarze et al. | Mar 2000 | A |
| 6068596 | Weth et al. | May 2000 | A |
| 6113560 | Simnacher | Sep 2000 | A |
| 6186963 | Schwarze et al. | Feb 2001 | B1 |
| 6217531 | Schwarze et al. | Feb 2001 | B1 |
| 6368292 | Ogden et al. | Apr 2002 | B1 |
| 6390995 | Ogden et al. | May 2002 | B1 |
| 6544987 | Guo et al. | Apr 2003 | B2 |
| 6881409 | Gold | Apr 2005 | B2 |
| 7189209 | Ogden | Mar 2007 | B1 |
| 7988648 | Warlick et al. | Aug 2011 | B2 |
| 20020002345 | Marlinghaus | Jan 2002 | A1 |
| 20040006288 | Spector | Jan 2004 | A1 |
| 20040059265 | Ogden et al. | Mar 2004 | A1 |
| 20040162508 | Candy et al. | Aug 2004 | A1 |
| 20050010140 | Forssmann | Jan 2005 | A1 |
| 20050075587 | Vago et al. | Apr 2005 | A1 |
| 20060036194 | Schultheiss | Feb 2006 | A1 |
| 20060036195 | Schultheiss | Feb 2006 | A1 |
| 20060051328 | Johnson | Mar 2006 | A1 |
| 20060100550 | Schultheiss | May 2006 | A1 |
| 20060100552 | Schultheiss | May 2006 | A1 |
| 20060246044 | Lutz | Nov 2006 | A1 |
| 20070016112 | Schultheiss | Jan 2007 | A1 |
| 20070142753 | Warlick | Jun 2007 | A1 |
| 20070239080 | Schaden | Oct 2007 | A1 |
| 20070239082 | Schultheiss | Oct 2007 | A1 |
| 20080269651 | Warlick | Oct 2008 | A1 |
| 20100324459 | Law | Dec 2010 | A1 |
| 20110034832 | Cioanta | Feb 2011 | A1 |
| 20120093764 | Maharaj | Apr 2012 | A1 |
| 20120215142 | Spector | Aug 2012 | A1 |
| 20130197404 | Spector | Aug 2013 | A1 |
| 20140257144 | Capelli | Sep 2014 | A1 |
| 20150073311 | Ein-Gal | Mar 2015 | A1 |
| 20170196766 | Spector | Jul 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 19721218 | Nov 1998 | DE |
| 10311659 | Sep 2004 | DE |
| 0243947 | Apr 1987 | EP |
| 1445758 | Aug 2004 | EP |
| 2005075020 | Aug 2005 | WO |
| 2006023498 | Feb 2006 | WO |
| Entry |
|---|
| Openstax College, “Anatomy & Physiology”, Apr. 25, 2013. |
| Definition of “treatment”, merriam-webster.com, captured on Dec. 5, 2020. |
| Definition of “treat”, google definition, captured on Dec. 5, 2020. |
| Press Release: FDA approves once-daily JANUVIA the first and only DPP-4 inhibitor available int eh united states for type 2 diabetes: http://www.januvia.com/sitagliptin_phosphate/januvia/hcp/press/index.jsp. |
| R.Meirer, et al; Extracorporal shock wave may enhance skin flap survival in an animal model; British Journal of Plastic Surgery; vol. 58, issue 1, Jan. 2005, pp. 53-57; copyright 2004; The British Association of Plastic Surgeons, published by Elsevier Ltd. |
| T.Nishida,et al; Extraporeal Cardiac Shock Wave Therapy Markedly Ameliorates Ischemia-Induced Myocardial Dysfunction in Pigs in Vivo; Circulation; Nov. 9, 2004; Circulation 2004; 110; pp. 3055-3061. |
| L.Gerdesmeyer, et al.; Antibacterial Effects of Extracorporeal Shock WAves; World Fed for Ultrasound in Medicine & Biology; printed USA, Elsevier, vol. 31 No. 1, pp. 115-119, 2005. |
| G.Haupt, et al; Effect of Shock Waves on the Healing of Partial-Thickness Wounds in Piglets; Journal of Surgical Research, vol. 49, No. 1, pp. 45-48, Jul. 1990; Copyright 1990 by Academic Press Inc. |
| Jagadeesh, G., et al; “Novel applications of micro-shock waves in biological sciences”; J.Indian Inst. Sci. 2002, 82, pp. 1-10. |
| Theil, M, et al; “The use of shock waves in medicine-a tool of the modern OR; an overview of basic phyusical principles, history and research”, Min Invas Ther & Allied Technol; 2000; 9(3/4) 247-253. |
| Huemer, Georg M., et al; “Comparison of the effectiveness of gene therapy with transforming growth factor-B or extracorporeal shock wave therapy to reduce ischemic necrosis in an epigastric skin flap model in rats”; Clinical Dept of Plastic and Reconstructive Surgery; Medical University Innsbruck Austria; Feb. 13, 2004; copyrt 2005 by the Wound Healing Society. ISSN: 1067-1927; wound rep reg 2005; 13:262-268. |
| Number | Date | Country | |
|---|---|---|---|
| 20170296427 A1 | Oct 2017 | US |
